Independent 5-year pharmaceutical and healthcare industry forecasts for Israel.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Israeli pharmaceutical and healthcare industry.
Competitive intelligence, Israeli pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Israeli market.
The Israel Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Its Israel Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Israeli pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark Its Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Israel to test other views – a key input for successful budgeting and strategic business planning in the Israeli pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Israeli Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Israel.
Exploit The Latest Competitive Israeli Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Israel.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Its forecast analysis, and taken together with Its Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
It 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke It economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
It 5-Year Macroeconomic Forecasts
It forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. It profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of Israel
Israel represents the most advanced pharmaceuticals sector in the Middle East. At US$179, annual per capita pharmaceutical spending is the highest in the region. The market is dominated by institutions, with the four main ‘not-for-profit’
Largely due to its sizeable generics industry, Israel has remained on the Office of the US Trade Representative (USTR)’s Priority Watch list of states infringing the rights of US patent holders. The continued low status of Israel is largely because of reforms to data protection laws and inadequate compensation for regulatory approval delays. Furthermore, the pricing and reimbursement system is another market access barrier; officials are reluctant to add novel products to the basket of centrallyfunded life-saving treatments. Due to its poor image with the research-based industry, the US association PhRMA is calling for Israel to be excluded from joining the OECD.
Israel has a substantial life sciences sector, and key reforms enacted in 2005 liberalised the sale of Israelioriginated technologies to foreign interests. Although the state is active in funding early-stage ventures, local developers are a strong target for the private sector, including research-based multinationals. It expects the biotech sector, which was worth approximately US$2bn in 2005, to go from strength to strength over the course of the next decade. If successful, the emergence of new life science technologies would help resolve Israel’s historic reliance on exports of generic products. The Manufacturers’
These strong prospects for the industry are reflected in Its regional Business Environment Ranking, which places Israel 7th of 14 markets surveyed in the region. Although the country remains isolated from many neighbouring states, multinationals may consider deeper involvement in local research as a potentially lucrative option. However, the market’s small size and relative maturity, the considerable share of sales and technical capacity of indigenous generic companies as well as the country’s periodic political and economic problems are considerable disincentives to investment.
For more information, Please visit :
http://www.bharatbook.com/
